Press Release – Appointment of Bernhard (W0027843-3).DOC
SANTA MONICA, CA, United States, via ETELIGIS INC., 06/03/2015 – – On June 3, 2015, Parallax Health Sciences, Inc. (“Parallax” or the “Company”) (OTCQB: PRLX), executed an Amendment to the Agreement to Purchase and Sell One Hundred Percent of the Issued and Outstanding Shares of a California Corporation (the “Pharmacy”) and Its Assets and Inventory (the “Purchase Agreement”) between the Company and the Pharmacy and its sole shareholder (the “Seller”).
Pursuant to the amendment, the Closing Date has been changed to September 30, 2015.
Certain terms and conditions of the Purchase Agreement remain confidential pursuant to a written non-disclosure agreement with the Seller until the Closing.
ABOUT PARALLAX HEALTH SCIENCES, INC.
Parallax Health Sciences, Inc., headquartered in Boston, MA, is a fully reporting Nevada corporation (OTCQB. PRLX). Parallax is a bio-medical company focused on infectious diseases. The Company owns a line of FDA approved Point of Care diagnostic tests on a single proprietary platform, and is developing a novel, handheld diagnostic testing system that is simple, rapid and elegant, offering the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians.
Parallax’s focus is on tests that detect and/or monitor infectious diseases, and combines innovative technologies that provide accessible, practical and rapid point of care in vitro diagnostics. The tests are based on the Company’s Target System, its FDA Approved Platform that is centered on the Target System VT1000, an FDA Approved bench top fluorescence immunoassay spectrum analyzer, and its innovative flow through Target System test cartridges. For more information: http://www.parallaxhealthsciences.com
ABOUT THE PHARMACY
The Pharmacy, established over 60 years ago, is a compound pharmacy, headquartered in California US, specializing in infertility treatments, specialized pain management and individualized treatments to its clientele. The Pharmacy has provided specialty compounding and full-service pharmaceutical services to healthcare professionals in over 40 states in the US.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond the Company’s control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in the Company’s reports filed with the SEC. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Parallax Health Sciences, Inc.
Parallax Health Sciences, Inc.
SOURCE: Parallax Health Sciences, Inc.